BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Credit Suisse
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $57.13 --0%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 33 | New: 6
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 33 | New: 6
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $111.00 (from $107.00) while maintaining a Outperform rating.
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- Nien Made Enterprise Co Ltd (8464:TT) PT Lowered to NT$480 at CLSA
- WW Grainger (GWW) PT Raised to $1,400 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
